{Reference Type}: Clinical Trial, Phase III
{Title}: A Randomized, Phase 3, Double-Blind, Crossover Comparison of Multilayer, Extended-Release Methylphenidate (PRC-063), and Lisdexamfetamine in the Driving Performance of Young Adults With ADHD.
{Author}: Madaan V;Bhaskar S;Donnelly GAE;Cox DJ;
{Journal}: J Atten Disord
{Volume}: 28
{Issue}: 6
{Year}: 2024 Apr 25
{Factor}: 3.196
{DOI}: 10.1177/10870547241226634
{Abstract}: <B>UNASSIGNED: </B>To compare PRC-063 (multilayer-release methylphenidate) and lisdexamfetamine dimesylate (LDX) on the driving performance of young adults with attention deficit hyperactivity disorder (ADHD) in a randomized, double-blind, crossover study.<BR><B>UNASSIGNED: </B>Following up to 21 days of each treatment in each treatment course (PRC-063/LDX or LDX/PRC-063), subjects completed a 15-hour driving simulator laboratory assessment. The primary outcome measure was the Tactical Driving Quotient (TDQ) and the Clinical Global Impressions-Improvement (CGI-I) scale was a secondary outcome measure.<BR><B>UNASSIGNED: </B>Forty-four subjects completed the study. PRC-063 and LDX had equivalent effects on driving performance through a 15-hour time period (least square mean difference -0.3 [standard error 1.08], 95% confidence interval [-2.4, 1.8], p = .793). Consistent improvement in CGI-I was observed. The incidence of treatment-emergent adverse events was similar for each treatment sequence.<BR><B>UNASSIGNED: </B>PRC-063 and LDX had comparable effects on driving performance, from 1 through 15 hours, the last time point measured.